These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28428503)

  • 21. Genetically modulating T-cell function to target cancer.
    Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
    Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell receptor gene therapy: critical parameters for clinical success.
    Linnemann C; Schumacher TN; Bendle GM
    J Invest Dermatol; 2011 Sep; 131(9):1806-16. PubMed ID: 21677669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TCR diversity - a universal cancer immunotherapy biomarker?
    McNeel DG
    J Immunother Cancer; 2016; 4():69. PubMed ID: 27879971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer.
    Straetemans T; Gründer C; Heijhuurs S; Hol S; Slaper-Cortenbach I; Bönig H; Sebestyen Z; Kuball J
    Clin Cancer Res; 2015 Sep; 21(17):3957-68. PubMed ID: 25991821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TCR repertoires of intratumoral T-cell subsets.
    Linnemann C; Mezzadra R; Schumacher TN
    Immunol Rev; 2014 Jan; 257(1):72-82. PubMed ID: 24329790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
    Magee MS; Snook AE
    Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells.
    Xu XJ; Tang YM
    Cancer Lett; 2014 Feb; 343(2):172-8. PubMed ID: 24141191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
    Li K; Lan Y; Wang J; Liu L
    Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active Immunotherapy of Cancer.
    Chodon T; Koya RC; Odunsi K
    Immunol Invest; 2015; 44(8):817-36. PubMed ID: 26575466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Supernatural T cells: genetic modification of T cells for cancer therapy.
    Kershaw MH; Teng MW; Smyth MJ; Darcy PK
    Nat Rev Immunol; 2005 Dec; 5(12):928-40. PubMed ID: 16322746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.
    Schmitt TM; Stromnes IM; Chapuis AG; Greenberg PD
    Clin Cancer Res; 2015 Dec; 21(23):5191-7. PubMed ID: 26463711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
    Eshhar Z
    Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.
    Thaxton JE; Li Z
    Hum Vaccin Immunother; 2014; 10(11):3313-21. PubMed ID: 25483644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering T cells for cancer therapy.
    Mansoor W; Gilham DE; Thistlethwaite FC; Hawkins RE
    Br J Cancer; 2005 Nov; 93(10):1085-91. PubMed ID: 16251873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
    Chicaybam L; Sodré AL; Bonamino M
    Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical development of T cell receptor gene therapy.
    Bendle GM; Haanen JB; Schumacher TN
    Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting T cell receptor genes for cancer immunotherapy.
    Xue S; Gillmore R; Downs A; Tsallios A; Holler A; Gao L; Wong V; Morris E; Stauss HJ
    Clin Exp Immunol; 2005 Feb; 139(2):167-72. PubMed ID: 15654813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.